Natixis’s TherapeuticsMD TXMD Stock Holding History

Natixis’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,600	Closed	-$28K	–	1334
2021 Q4	$28K	Hold	1,600	–	–	﹤0.01%	1204
2021 Q3	$59K	Buy	+1,600	New	+$71K	﹤0.01%	1173
2021 Q2	–	Sell	-900	Closed	-$60K	–	1054
2021 Q1	$60K	Buy	900 +180	+25%	+$14.1K	﹤0.01%	1048
2020 Q4	$44K	Buy	+720	New	+$49.2K	﹤0.01%	1026
2017 Q4	–	Sell	-389	Closed	-$103K	–	1178
2017 Q3	$103K	Buy	+389	New	+$112K	﹤0.01%	1185

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Natixis's TXMD Position: Q1 2022 in Review

Natixis sold out of TherapeuticsMD (TXMD) in Q1 2022, closing a stake of 1,600 shares — an estimated $28K sold.

Natixis first reported a position in TXMD in Q3 2017 and held it in 5 quarters. The position peaked at $103K in Q3 2017. 124 funds tracked by Wall St. Rank hold TXMD as of Q1 2022.

Natixis reported no remaining TherapeuticsMD position as of Q1 2022 after selling out during the quarter.
Natixis sold 1,600 TherapeuticsMD shares in Q1 2022, an estimated $28K.
Natixis first reported a position in TherapeuticsMD in Q3 2017 and held it in 5 quarters.
Natixis's TherapeuticsMD position peaked at $103K in Q3 2017.
124 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.